Generate Biomedicines, Inc. GENB
Set alert
14.13 USD +0.92 +6.93%
As of Nov 3, 9:56 AM ET
13.33 Day range 14.17
11.00 52-week range 22.67
- YTD
- +11.67%
- 1 year
- +11.67%
- Open
- 13.33
- Prev close
- 13.21
- Mkt cap
- 1.81B
- Vol
- 74.68K
- Avg vol
- 1.19M
- EPS
- -2.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.33
- High
- 14.17
- Forward P/E
- -5.79
- Beta
- 0.00
- Short ratio
- 7.37
- Inst. own
- 82.15%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 15.00
- 200-d avg
- 14.07
- 1y target
- 27.00
5D chart
Signals (114)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 3:35 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 3:20 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 3:15 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 3:10 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 2:55 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 2:45 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 2:40 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 2:20 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 2:05 PM | 19 hours ago |
| MACD: Buy Signal | Nov 2, 2:00 PM | 19 hours ago |
| MACD: Sell Signal | Nov 2, 1:15 PM | 20 hours ago |
| RSI: Oversold | Nov 2, 1:15 PM | 20 hours ago |
| SMA: Bearish | Nov 2, 12:20 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 12:15 PM | 21 hours ago |
| SMA: Bearish | Nov 2, 12:05 PM | 21 hours ago |
| MACD: Buy Signal | Nov 2, 11:50 AM | 22 hours ago |
| SMA: Bullish | Nov 2, 11:30 AM | 22 hours ago |
| RSI: Oversold | Nov 2, 10:55 AM | 23 hours ago |
| SMA: Bearish | Nov 2, 10:30 AM | 23 hours ago |
| SMA: Bearish | Nov 2, 10:30 AM | 23 hours ago |
Newest 20 of 114.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 27.00 +91.1% upside
Now 14.13
- Target (low)
- 22.00
- Target (mean)
- 27.00
- Target (high)
- 30.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.545 | -0.67 – -0.44 | 0.00 | 0.0% | 7.75M | 0.0% | 4 |
| Next quarter | -0.5675 | -0.63 – -0.44 | 0.00 | 0.0% | 7.65M | 0.0% | 4 |
| Current year | -2.30 | -2.50 – -2.14 | 0.00 | 0.0% | 29.68M | 0.0% | 4 |
| Next year | -2.28 | -2.72 – -1.53 | -2.30 | +0.9% | 23.83M | -19.7% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 8, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 28, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 14, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 8, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 13, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Mar 24, 2026 | Goldman Sachs | Initiated | — | Buy |
| Mar 24, 2026 | Morgan Stanley | Initiated | — | Overweight |
| Mar 24, 2026 | Piper Sandler | Initiated | — | Overweight |
| Mar 24, 2026 | Cantor Fitzgerald | Initiated | — | Overweight |
| Mar 24, 2026 | Guggenheim | Initiated | — | Buy |